Literature DB >> 33827579

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.

Boyang Xiang1,1, Xiaoya Zhao1,1, Xiang Zhou2,2.   

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) suggested that these benefits are independent of glycemic control. Several large-scale outcome trials of SGLT2i also showed cardiovascular benefits in nondiabetic patients, strengthening this perspective. Extensive animal and clinical studies have likewise shown that mechanisms other than the antihyperglycemic effect underlie the cardiovascular benefits. Recent clinical guidelines recommend the use of SGLT2i in patients with type 2 diabetes mellitus and cardiovascular diseases because of the proven cardiovascular protective effects. Since the cardiovascular benefits are independent of glycemic control, the therapeutic spectrum of SGLT2i will likely be extended to nondiabetic patients.

Entities:  

Keywords:  Cardiovascular benefits; Diabetes; Sodium-glucose cotransporter 2 inhibitors

Year:  2021        PMID： 33827579     DOI： 10.1186/s12933-021-01266-x

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN： 1475-2840            Impact factor:   9.951


  143 in total

1.  The relation of glycosuria to glycaemia and the determination of the renal threshold for glucose.

Authors:  H P Himsworth
Journal:  Biochem J       Date:  1931       Impact factor: 3.857

2.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.

Authors:  Rodney A Hayward; Peter D Reaven; Wyndy L Wiitala; Gideon D Bahn; Domenic J Reda; Ling Ge; Madeline McCarren; William C Duckworth; Nicholas V Emanuele
Journal:  N Engl J Med       Date:  2015-06-04       Impact factor: 91.245

Review 3.  Biology of human sodium glucose transporters.

Authors:  Ernest M Wright; Donald D F Loo; Bruce A Hirayama
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

4.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

Review 5.  Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Authors:  George L Bakris; Vivian A Fonseca; Kumar Sharma; Ernest M Wright
Journal:  Kidney Int       Date:  2009-04-08       Impact factor: 10.612

Review 6.  Glucose control by the kidney: an emerging target in diabetes.

Authors:  Olivera Marsenic
Journal:  Am J Kidney Dis       Date:  2009-03-26       Impact factor: 8.860

7.  Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Authors:  B Komoroski; N Vachharajani; Y Feng; L Li; D Kornhauser; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2009-01-07       Impact factor: 6.875

8.  Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.

Authors:  Timo Rieg; Takahiro Masuda; Maria Gerasimova; Eric Mayoux; Kenneth Platt; David R Powell; Scott C Thomson; Hermann Koepsell; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-13

9.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

10.  Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Authors:  Jiwen Jim Liu; TaeWeon Lee; Ralph A DeFronzo
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461
View more
  2 in total

1.  Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease.

Authors:  Xueliang Wang; Zhe Wang; Di Liu; Hao Jiang; Chao Cai; Guoyun Li; Guangli Yu
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

Review 2.  A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection.

Authors:  Shafaat Raza; Stephen Osasan; Sudiksha Sethia; Tayyaba Batool; Zarna Bambhroliya; Joel Sandrugu; Michael Lowe; Oluwasemilore Okunlola; Pousette Hamid
Journal:  Cureus       Date:  2022-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.